Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxaliplatin - Dr Reddy's Laboratories/Pfizer/Sanofi/Yakult Honsha

Drug Profile

Oxaliplatin - Dr Reddy's Laboratories/Pfizer/Sanofi/Yakult Honsha

Alternative Names: 1 OHP; 1670 RB7; Dacotin; Dacplat; Eloxatin; Elplat; NSC 266046; Oxalatoplatin; Oxalatoplatinum; RP 54780; SR 96669

Latest Information Update: 07 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nagoya University
  • Developer Alliance for Clinical Trials in Oncology; Beth Israel Deaconess Medical Center; Chugai Pharmaceutical; Dana-Farber Cancer Institute; Debiopharm; Dr Reddys Laboratories; Pfizer; Sanofi; University of California at Irvine; University of Southern California; University of Texas M. D. Anderson Cancer Center; Yakult Honsha
  • Class Antineoplastics; Platinum complexes; Small molecules
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Colorectal cancer
  • Registered Gastric cancer; Liver cancer; Pancreatic cancer
  • Phase II Germ cell and embryonal neoplasms; Head and neck cancer; Intestinal cancer; Oesophageal cancer; Ovarian cancer; Testicular cancer; Uterine cancer
  • Discontinued Acute myeloid leukaemia; Breast cancer; Diffuse large B cell lymphoma; Myelodysplastic syndromes; Nasopharyngeal cancer; Non-small cell lung cancer

Most Recent Events

  • 21 Dec 2018 Yakult Honsha completes a phase II trial for Colorectal cancer (Combination therapy, Adjuvant therapy) in Japan (IV, Infusion) (UMIN000012618)
  • 27 Apr 2018 Sanofi terminates a phase II trial due to slow accrual in Head and neck cancer (Adjuvant therapy) in USA (IV) (NCT00256308)
  • 01 Sep 2017 Phase-II clinical trials in Gastric cancer (Combination therapy, Late-stage disease, Metastatic disease) in Japan (IV) (UMIN000028749)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top